For World Blood Cancer Day this May 28 — a day when advocates around the globe join forces to raise awareness…
News
Following “encouraging findings” from an early study, Can-Fite Biopharma is planning a clinical trial to test…
A Phase 1 clinical trial testing TLX101-Tx, Telix Pharmaceuticals‘ experimental treatment for glioblastoma (an aggressive form of glioma), has completed enrollment. The study,…
A large clinical trial testing Merck’s therapy candidate sacituzumab tirumotecan (sac-TMT) in people with hard-to-treat endometrial cancer has achieved its main goal, with sac-TMT…
A Phase 1 clinical trial testing the experimental therapy KLN-1010 in people with relapsed or refractory multiple myeloma has begun treating patients in the…
The U.S. Food and Drug Administration (FDA) has approved a new combination therapy — Inqovi (decitabine and cedazuridine) plus Venclexta (venetoclax) — to treat adults…
The U.S. Food and Drug Administration (FDA) has given Actuate Therapeutics the green light to begin a clinical trial testing an oral formulation of…
In an early clinical trial testing the novel therapy Alpha DaRT for recurrent glioblastoma, the first three patients given the radiation treatment all showed a…
Liraltagene autoleucel (lira-cel), an experimental cell therapy in clinical development for recurrent ovarian cancer, has been tolerated well so far in an early clinical trial,…
Cellcentric has raised $220 million in financing to support two clinical trials testing its potentially first-in-class oral therapy inobrodib in people with hard-to-treat…
